Advisory Commission on Childhood Vaccines, Notice of Meeting, 52041 [2012-21093]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 167 / Tuesday, August 28, 2012 / Notices
R. Record Source Categories
Information in this system is obtained
from many sources, including the
following: (1) Directly from the
respondent or complainant or his/her
representative; (2) derived from
materials supplied by the respondent or
complainant or his/her representative;
(3) from information supplied by the
institutions, witnesses, scientific
publications, and other
nongovernmental sources; (4) from
observation and analysis made by FDA
and ORI staff and scientific experts; (5)
from departmental and other Federal,
State, and local government records; (6)
from hearings and other administrative
proceedings; and (7) from any other
relevant source.
srobinson on DSK4SPTVN1PROD with NOTICES
S. Records Exempted From Certain
Provisions of the Privacy Act
FDA records related to research
misconduct proceedings will be exempt
from the Privacy Act requirements
pertaining to providing an accounting of
disclosures, access and amendment,
notification, and Agency procedures
and rules under sections 552a(k)(2) and
(k)(5) of the Privacy Act.
Elsewhere in this issue of the Federal
Register, FDA is publishing a notice of
proposed rulemaking and direct final
rule to apply these exemptions to
records in this system related to ongoing
investigations or that would reveal a
confidential source. These exemptions
are necessary to safeguard the integrity
of the research misconduct proceedings
and to ensure that FDA’s efforts to
obtain accurate and objective
information will not be hindered. In the
course of investigations of allegations of
research misconduct, it is often
necessary to give an express promise to
withhold the identity of an individual
who has provided relevant information.
Sources of information necessary to
complete an effective investigation may
be reluctant to provide sensitive
information unless they can be assured
that their identities will not be revealed.
The proposed exemptions will ensure
that the records related to ongoing
investigations will not be disclosed
inappropriately and that the identities
of confidential sources will be
protected.
The notice of proposed rulemaking
and direct final rule provide additional
detail regarding the bases for these
exemptions.
II. Comments
FDA invites comments on all parts of
the systems notice. Interested persons
may submit to the Division of Dockets
Management (see ADDRESSES) either
VerDate Mar<15>2010
16:39 Aug 27, 2012
Jkt 226001
electronic or written comments
regarding this document. It is only
necessary to send one set of comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: June 12, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012–20888 Filed 8–27–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Commission on Childhood
Vaccines, Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: Advisory Commission on
Childhood Vaccines (ACCV).
Date and Time: September 06, 2012,
1:00 p.m. to 5:15 p.m. EDT.
Place: Parklawn Building (and via
audio conference call), Conference
Room 10–65, 5600 Fishers Lane,
Rockville, MD 20857.
The ACCV will meet on Thursday,
September 06 from 1:00 p.m. to 5:15
p.m. (EDT). The public can join the
meeting via audio conference call by
dialing 1–800–369–3104 on September
06, and providing the following
information:
Leader’s Name: Dr. Geoffrey Evans
Password: ACCV
Agenda: The agenda items for the
September meeting will include, but are
not limited to: Updates from the
Division of Vaccine Injury
Compensation (DVIC), Department of
Justice (DOJ), National Vaccine Program
Office (NVPO), Immunization Safety
Office (Centers for Disease Control and
Prevention), National Institute of
Allergy and Infectious Diseases
(National Institutes of Health) and
Center for Biologics Evaluation and
Research (Food and Drug
Administration). A draft agenda and
additional meeting materials will be
posted on the ACCV web site (https://
www.hrsa.gov/vaccinecompensation/
accv.htm) prior to the meeting. Agenda
items are subject to change as priorities
dictate.
Public Comment: Persons interested
in attending the meeting in person or
providing an oral presentation should
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
52041
submit a written request, along with a
copy of their presentation to: Annie
Herzog, DVIC, Healthcare Systems
Bureau (HSB), Health Resources and
Services Administration (HRSA), Room
11C–26, 5600 Fishers Lane, Rockville,
Maryland 20857 or email:
aherzog@hrsa.gov. Requests should
contain the name, address, telephone
number, email address, and any
business or professional affiliation of
the person desiring to make an oral
presentation. Groups having similar
interests are requested to combine their
comments and present them through a
single representative. The allocation of
time may be adjusted to accommodate
the level of expressed interest. DVIC
will notify each presenter by email,
mail, or telephone of their assigned
presentation time. Persons who do not
file an advance request for a
presentation, but desire to make an oral
statement, may announce it at the time
of the public comment period. Public
participation and ability to comment
will be limited to space and time as
available.
FOR FURTHER INFORMATION CONTACT:
Anyone requiring information regarding
the ACCV should contact Annie Herzog,
DVIC, HSB, HRSA, Room 11C–26, 5600
Fishers Lane, Rockville, MD 20857;
telephone (301) 443–6593, or email:
aherzog@hrsa.gov.
Dated: August 22, 2012.
Bahar Niakan,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2012–21093 Filed 8–27–12; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 77, Number 167 (Tuesday, August 28, 2012)]
[Notices]
[Page 52041]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-21093]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Advisory Commission on Childhood Vaccines, Notice of Meeting
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), notice is hereby given of the following
meeting:
Name: Advisory Commission on Childhood Vaccines (ACCV).
Date and Time: September 06, 2012, 1:00 p.m. to 5:15 p.m. EDT.
Place: Parklawn Building (and via audio conference call),
Conference Room 10-65, 5600 Fishers Lane, Rockville, MD 20857.
The ACCV will meet on Thursday, September 06 from 1:00 p.m. to 5:15
p.m. (EDT). The public can join the meeting via audio conference call
by dialing 1-800-369-3104 on September 06, and providing the following
information:
Leader's Name: Dr. Geoffrey Evans
Password: ACCV
Agenda: The agenda items for the September meeting will include,
but are not limited to: Updates from the Division of Vaccine Injury
Compensation (DVIC), Department of Justice (DOJ), National Vaccine
Program Office (NVPO), Immunization Safety Office (Centers for Disease
Control and Prevention), National Institute of Allergy and Infectious
Diseases (National Institutes of Health) and Center for Biologics
Evaluation and Research (Food and Drug Administration). A draft agenda
and additional meeting materials will be posted on the ACCV web site
(https://www.hrsa.gov/vaccinecompensation/accv.htm) prior to the
meeting. Agenda items are subject to change as priorities dictate.
Public Comment: Persons interested in attending the meeting in
person or providing an oral presentation should submit a written
request, along with a copy of their presentation to: Annie Herzog,
DVIC, Healthcare Systems Bureau (HSB), Health Resources and Services
Administration (HRSA), Room 11C-26, 5600 Fishers Lane, Rockville,
Maryland 20857 or email: aherzog@hrsa.gov. Requests should contain the
name, address, telephone number, email address, and any business or
professional affiliation of the person desiring to make an oral
presentation. Groups having similar interests are requested to combine
their comments and present them through a single representative. The
allocation of time may be adjusted to accommodate the level of
expressed interest. DVIC will notify each presenter by email, mail, or
telephone of their assigned presentation time. Persons who do not file
an advance request for a presentation, but desire to make an oral
statement, may announce it at the time of the public comment period.
Public participation and ability to comment will be limited to space
and time as available.
FOR FURTHER INFORMATION CONTACT: Anyone requiring information regarding
the ACCV should contact Annie Herzog, DVIC, HSB, HRSA, Room 11C-26,
5600 Fishers Lane, Rockville, MD 20857; telephone (301) 443-6593, or
email: aherzog@hrsa.gov.
Dated: August 22, 2012.
Bahar Niakan,
Director, Division of Policy and Information Coordination.
[FR Doc. 2012-21093 Filed 8-27-12; 8:45 am]
BILLING CODE 4165-15-P
